143 related articles for article (PubMed ID: 14982868)
1. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation.
Kröger N; Schilling G; Einsele H; Liebisch P; Shimoni A; Nagler A; Perez-Simon JA; San Miguel JF; Kiehl M; Fauser A; Schwerdtfeger R; Wandt H; Sayer HG; Myint H; Klingemann H; Zabelina T; Dierlamm J; Hinke A; Zander AR
Blood; 2004 Jun; 103(11):4056-61. PubMed ID: 14982868
[TBL] [Abstract][Full Text] [Related]
2. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
Schilling G; Hansen T; Shimoni A; Zabelina T; Pérez-Simón JA; Gutierrez NC; Bethge W; Liebisch P; Schwerdtfeger R; Bornhäuser M; Otterstetter S; Penas EM; Dierlamm J; Ayuk F; Atanackovic D; Bacher U; Bokemeyer C; Zander A; San Miguel J; Nagler A; Kröger N
Leukemia; 2008 Jun; 22(6):1250-5. PubMed ID: 18418408
[TBL] [Abstract][Full Text] [Related]
3. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
[TBL] [Abstract][Full Text] [Related]
4. Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma.
Worel N; Greinix H; Ackermann J; Kaufmann H; Urbauer E; Höcker P; Gisslinger H; Lechner K; Kalhs P; Drach J
Ann Hematol; 2001 Jun; 80(6):345-8. PubMed ID: 11475148
[TBL] [Abstract][Full Text] [Related]
5. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization.
Zojer N; Königsberg R; Ackermann J; Fritz E; Dallinger S; Krömer E; Kaufmann H; Riedl L; Gisslinger H; Schreiber S; Heinz R; Ludwig H; Huber H; Drach J
Blood; 2000 Mar; 95(6):1925-30. PubMed ID: 10706856
[TBL] [Abstract][Full Text] [Related]
6. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
7. Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma.
Kaufmann H; Krömer E; Nösslinger T; Weltermann A; Ackermann J; Reisner R; Bernhart M; Drach J
Eur J Haematol; 2003 Sep; 71(3):179-83. PubMed ID: 12930318
[TBL] [Abstract][Full Text] [Related]
8. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy.
Fonseca R; Oken MM; Harrington D; Bailey RJ; Van Wier SA; Henderson KJ; Kay NE; Van Ness B; Greipp PR; Dewald GW
Leukemia; 2001 Jun; 15(6):981-6. PubMed ID: 11417487
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
Sagaster V; Ludwig H; Kaufmann H; Odelga V; Zojer N; Ackermann J; Küenburg E; Wieser R; Zielinski C; Drach J
Leukemia; 2007 Jan; 21(1):164-8. PubMed ID: 17096015
[TBL] [Abstract][Full Text] [Related]
10. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
11. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.
Bock F; Lu G; Srour SA; Gaballa S; Lin HY; Baladandayuthapani V; Honhar M; Stich M; Shah ND; Bashir Q; Patel K; Popat U; Hosing C; Korbling M; Delgado R; Rondon G; Shah JJ; Thomas SK; Manasanch EE; Isermann B; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2159-2164. PubMed ID: 27638366
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.
Lee CK; Badros A; Barlogie B; Morris C; Zangari M; Fassas A; van Rhee F; Cottler-Fox M; Jacobson J; Thertulien R; Muwalla F; Mazher S; Anaissie E; Tricot G
Exp Hematol; 2003 Jan; 31(1):73-80. PubMed ID: 12543109
[TBL] [Abstract][Full Text] [Related]
13. [The significances of 13q14 deletion for development and prognosis of multiple myeloma].
Li Q; An G; Li CW; Xu Y; Deng SH; Liu XP; Qi JY; Wang YF; Zou DH; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):217-20. PubMed ID: 21569701
[TBL] [Abstract][Full Text] [Related]
14. [Chromosome 13q deletion detected by interphase FISH in multiple myeloma: a study of 100 cases in China].
Li Q; Lu Y; Wang YF; Liu XP; Qi JY; Zou DH; Zhao YZ; Qiu LG
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(28):1979-82. PubMed ID: 19950573
[TBL] [Abstract][Full Text] [Related]
15. The clinical characteristics and prognosis of IGH deletion in multiple myeloma.
He H; Fu W; Jiang H; Du J; Zhou L; Zhang C; Xi H; Li R; Hou J
Leuk Res; 2015 May; 39(5):515-9. PubMed ID: 25817540
[TBL] [Abstract][Full Text] [Related]
16. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
Königsberg R; Zojer N; Ackermann J; Krömer E; Kittler H; Fritz E; Kaufmann H; Nösslinger T; Riedl L; Gisslinger H; Jäger U; Simonitsch I; Heinz R; Ludwig H; Huber H; Drach J
J Clin Oncol; 2000 Feb; 18(4):804-12. PubMed ID: 10673522
[TBL] [Abstract][Full Text] [Related]
17. Effect of 13q deletion on IL-6 production in patients with multiple myeloma: a hypothesis may hold true.
Neemat K; Rania K; Tarek M; Hamdy AA
Clin Lab; 2014; 60(8):1393-9. PubMed ID: 25185427
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
[TBL] [Abstract][Full Text] [Related]
19. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J
Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939
[TBL] [Abstract][Full Text] [Related]
20. Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance.
Königsberg R; Ackermann J; Kaufmann H; Zojer N; Urbauer E; Krömer E; Jäger U; Gisslinger H; Schreiber S; Heinz R; Ludwig H; Huber H; Drach J
Leukemia; 2000 Nov; 14(11):1975-9. PubMed ID: 11069034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
